Evolution and Clinical Impact of EGFR Mutations in Circulating Free DNA in the BELIEF Trial-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Evolution and Clinical Impact of EGFR Mutations in Circulating Free DNA in the BELIEF Trial

Published:2020-03 Issue:3 Volume:15 Page:416-425
ISSN:1556-0864
Container-title:Journal of Thoracic Oncology
language:en
Short-container-title:Journal of Thoracic Oncology

Author:

Molina-Vila Miguel-Angel,Stahel Rolf A.,Dafni Urania,Jordana-Ariza Núria,Balada-Bel Ariadna,Garzón-Ibáñez Mónica,García-Peláez Beatriz,Mayo-de-las-Casas Clara,Felip Enriqueta,Curioni Fontecedro Alessandra,Gautschi Oliver,Peters Solange,Massutí Bartomeu,Palmero Ramon,Ponce Aix Santiago,Carcereny Enric,Früh Martin,Pless Miklos,Popat Sanjay,Cuffe Sinead,Bidoli Paolo,Kammler Roswitha,Roschitzki-Voser Heidi^ORCID,Tsourti Zoi,Karachaliou Niki,Rosell Rafael

Funder

Abbvie

Astra Zeneca

BMS

Boehringer Ingelheim

Merck Sharp and Dohme

Novartis

Pfizer

Roche

Merck

F. Hoffmann-La Roche

Seattle Genetics

AstraZeneca

Genentech

Bristol-Myers Squibb

Celgene

Lilly

Merck KGaA

Samsung

Amgen

Bayer

Daiichi Sankyo

Illumina

Regeneron

Sanofi

EMD Serono

European Thoracic Oncology

Institute of Cancer Research

Biomedical Research Centre

Publisher

Elsevier BV

Subject

Pulmonary and Respiratory Medicine,Oncology

Reference36 articles.

1. Lung cancer: using ctDNA to track EGFR and KRAS mutations in advanced-stage disease;Rosell;Nat Rev Clin Oncol,2016

2. Liquid biopsy for advanced non-small cell lung cancer (NSCLC): a statement paper from the IASLC;Rolfo;J Thorac Oncol,2018

3. Epidermal growth factor receptor mutation status in circulating free DNA in serum: from IPASS, a phase III study of gefitinib or carboplatin/paclitaxel in non-small cell lung cancer;Goto;J Thorac Oncol,2012

4. Epidermal growth factor receptor mutations in plasma DNA samples predict tumor response in Chinese patients with stages IIIB to IV non-small-cell lung cancer;Bai;J Clin Oncol,2009

5. Detection of epidermal growth factor receptor mutations in serum as a predictor of the response to gefitinib in patients with non-small-cell lung cancer;Kimura;Clin Cancer Res,2006

Cited by 15 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Adaptive therapy to circumvent drug resistance to tyrosine kinase inhibitors in cancer: is it clinically relevant?;Expert Review of Anticancer Therapy;2022-11-24

2. Changes in the concentration of EGFR-mutated plasma DNA in the first hours of targeted therapy allow the prediction of tumor response in patients with EGFR-driven lung cancer;International Journal of Clinical Oncology;2022-02-16

3. The EPICAL trial, a phase Ib study combining first line afatinib with anti-EGF vaccination in EGFR-mutant metastatic NSCLC;Lung Cancer;2022-02

4. Role of Circulating Tumor DNA Profiling in Patients with Non-Small Cell Lung Cancer Treated with EGFR Inhibitor;Oncology;2022

5. First-line osimertinib in patients with epidermal growth factor receptor–mutant non–small-cell lung cancer and with a coexisting low allelic fraction of Thr790Met;European Journal of Cancer;2021-12

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3